#United States #Minneapolis #Neuromodulation #Saluda Medical #Evoke System

Saluda Medical's Major Financing Milestone

On January 10, 2025, Saluda Medical, Inc., a prominent medical device company with a focus on developing cutting-edge treatments for chronic neurological conditions, announced the successful closure of a $100 million financing round. This milestone is a significant step in the company’s commitment to advancing its groundbreaking neuromodulation technology.

The financing was spearheaded by Redmile Group, a loyal investor, with significant support from notable firms such as Wellington Management, TPG Life Sciences Innovation, and Fidelity Management & Research Company. Additionally, Piper Heartland Healthcare Capital emerged as a new investor in this funding round.

Purpose of the Financing

The primary objective of this financing is the commercialization of the Evoke® System, which represents a major leap in the treatment of chronic pain management. The Evoke® System is the first commercial application stemming from Saluda’s proprietary closed-loop, dose-control neuromodulation platform. Chronic pain is a critical global health issue, affecting more than 20% of the world's population and an estimated 67 million individuals in the United States alone.

The Evoke® System Explained

The Evoke® System stands out as a revolutionary device designed for spinal cord stimulation (SCS), offering a physiological closed-loop, dose-control mechanism specifically aimed at managing chronic pain. Unlike conventional therapies, the Evoke® System is unique in its capability to sense and measure neural responses to stimulation. It dynamically adjusts treatment in real-time to maintain an optimal level of neural activation tailored to each patient's specific needs. This advancement ensures a consistent therapeutic effect, leading to improved patient outcomes and overall satisfaction.

Chronic pain management is an area that has long faced challenges, with traditional methods often falling short in efficacy. The ability of the Evoke® System to maintain a target level of neural activation is groundbreaking, providing patients with more reliable and personalized care.

Saluda Medical's Vision

Founded on the principles of innovation and patient-centered care, Saluda Medical aims to redefine chronic pain treatment through advanced neuromodulation technologies. The company’s closed-loop platform not only measures neural feedback but also applies this information to optimize therapy effectively. This function bridges the gap in current treatment methods, reducing both patient and clinician burdens associated with chronic pain management.

Preliminary results from several extensive studies, including those published in The Lancet Neurology, JAMA Neurology, and Regional Anesthesia and Pain Medicine, showcase the remarkable potential of the Evoke® System. These studies underline the enduring efficacy of the device in providing pain relief over significant periods, firmly establishing its role in future pain management protocols.

Summary

With the closing of this substantial financing, Saluda Medical is poised to make a considerable impact on the landscape of chronic pain management. The company leverages its robust financial backing to ensure the successful launch and widespread adoption of the Evoke® System. As patient needs continue to evolve, the innovative solutions provided by Saluda Medical are expected to shape the future of treatment for chronic pain, offering hope and relief to millions worldwide.

For those interested in learning more about the risks and the important safety information pertaining to the Evoke® System, detailed disclosures can be found on Saluda Medical's official website.